Abstract
Fucoxanthin (FX) is a marine carotenoid from brown algae that is metabolized in the body into fucoxanthinol (FXOH) and amarouciaxanthin A (AXA). Previous studies state that FX exhibits strong antioxidant activity, reduces free fatty acid synthesis, and modulates lipid metabolism. However, its inhibitory potential on SREBP Cleavage-Activating Protein (SCAP) remains unexplored. This study employed in silico techniques to assess the binding efficiency of FX and its derivatives against SCAP, using fatostatin and UT-59 as reference inhibitors. ADME profiling revealed that all natural ligands were lipophilic and poorly water-soluble. Molecular docking showed that AXA had the strongest binding affinity (-7.543 kcal/mol), followed by UT-59 (-6.846 kcal/mol), fatostatin (-5.743 kcal/mol), FXOH (-4.853 kcal/mol), and FX (-4.175 kcal/mol). AXA formed a key hydrogen bond with residue A268 in the SCAP luminal domain. Molecular dynamics simulations over 100 ns confirmed stable protein-ligand interactions, with RMSD values ranging between 7.5 and 9 Å. MM-GBSA binding free energy for FX (-55.09 kcal/mol) and AXA (-35.86 kcal/mol) supported their favorable interactions. Fucoxanthin derivatives, especially AXA, demonstrate promising SCAP inhibitory potential and could be explored further for natural, cholesterol-lowering therapeutics. Further, in vitro and in vivo experimental validations are needed for natural drug formulation.

This publication has 38 references indexed in Scilit: